Nuvectis Pharma (NVCT) KOL Event summary

Introduction and agenda

• The event focused on the NXP900 phase 1b program in advanced solid tumors, including combination with osimertinib in non-small cell lung cancer, and outlined the agenda with expert speakers and a Q&A session.

• Forward-looking statements were made regarding the timing and data for the NXP900 phase 1b study, with associated risks highlighted.

• The agenda included a welcome, NXP900 mechanism of action overview, clinical program, KOL presentations, and Q&A.

KOL background and credentials

• Dr. Asier Unciti-Broceta, a medicinal chemist and director at the University of Edinburgh, is the discoverer of NXP900.

• Dr. Alexander Spira, Chief Scientific Officer at Next Oncology, is an experienced clinical oncologist specializing in thoracic cancer and EGFR inhibitor development.

• Speakers included Ron Bentsur (CEO), Prof. Asier Unciti-Broceta, and Dr. Alexander Spira.

Market insights and analysis

• NXP900 targets a large addressable population, estimated at 45,000 patients in non-small cell lung cancer alone.

• There is a significant unmet need in both EGFR-mutated and non-mutated lung cancer populations, with current therapies limited by toxicity and resistance.

• NSCLC treatment paradigms highlight significant unmet needs, especially in 2nd line where survival outcomes with docetaxel remain poor.

• FLAURA2 and MARIPOSA studies show evolving standards in EGFR-mutated NSCLC, with long-term survival but persistent gaps post-progression.

• Substantial opportunity exists for new oral therapies, especially for patients with recurrent disease and specific genetic alterations.